Portfolio News


May 2014

SV Life Sciences Fund V invested in Avitide as part of a $3.4m Series B financing round. Avitide is a biopharmaceutical company dedicated to the discovery and development of affinity purification products that will improve the fundamental timeframes and economics of commercial bioprocessing.  

Team - Michael Ross

⇧ Back to top